[B细胞分化标志物对原发性中枢神经系统淋巴瘤预后的影响]
[Effect of B Cell Differentiation Markers on the Prognosis of Primary Central Nervous System Lymphoma].
作者信息
Chen Xiang-Lei, Li Xiao-Yun, Wang Wei
机构信息
Department of Radio Therapy, Yidu Central Hospital of Weifang, Weifang 262500, Shangdong Province, China.
Department of Neurology, Yidu Central Hospital of Weifang, Weifang 262500, Shangdong Province, China.
出版信息
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017 Oct;25(5):1410-1414. doi: 10.7534/j.issn.1009-2137.2017.05.022.
OBJECTIVE
To investigate the value of B-cell differentiation markers in prognosis evaluation of 119 patients with primary CNS lymphoma(PCNSL).
METHODS
The expressions of BCL-2, BCL-6, CD10 and MUM1/IRF4 protein were determined by immunohistochemistry, and their relationship with the prognosis of primary central nervous system lymphoma was analyzed.
RESULTS
Univariate analysis showed that BCL-6 positive means shorter PFS (P=0.047) and OS (P=0.035). Multivariate analysis showed that BCL-6 positive expression was related with shorter PFS (hazard ratio:1.95, 95% CI: 1.22- 3.12, P=0.005), but did not relate with OS (hazard ratio: 1.85, 95% CI: 0.71- 4.80, P=0.21). Classification based on Hans algorithm and expression status of the single B-cell markers BCL-2, CD10 and MUM1/IRF4 did not correlate with prognosis.
CONCLUSION
BCL-6 may be an unfavorable prognostic biomarker for PCNSL.
目的
探讨B细胞分化标志物在119例原发性中枢神经系统淋巴瘤（PCNSL）预后评估中的价值。
方法
采用免疫组织化学法检测BCL-2、BCL-6、CD10和MUM1/IRF4蛋白的表达，并分析其与原发性中枢神经系统淋巴瘤预后的关系。
结果
单因素分析显示，BCL-6阳性意味着无进展生存期（PFS）较短（P=0.047）和总生存期（OS）较短（P=0.035）。多因素分析显示，BCL-6阳性表达与较短的PFS相关（风险比：1.95，95%置信区间：1.22-3.12，P=0.005），但与OS无关（风险比：1.85，95%置信区间：0.71-4.80，P=0.21）。基于Hans算法以及单个B细胞标志物BCL-2、CD10和MUM1/IRF4的表达状态进行分类与预后无关。
结论
BCL-6可能是PCNSL的不良预后生物标志物。
Zotero 插件